IMMUNIC INC
NASDAQ: IMUX (Immunic, Inc.)
Last update: 11 hours ago13.71
-0.30 (-2.14%)
| Previous Close | 14.01 |
| Open | 14.13 |
| Volume | 118,325 |
| Avg. Volume (3M) | 269,108 |
| Market Cap | 186,750,528 |
| Price / Book | 1.26 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Diluted EPS (TTM) | -0.950 |
| Total Debt/Equity (MRQ) | 5.45% |
| Current Ratio (MRQ) | 0.740 |
| Operating Cash Flow (TTM) | -82.57 M |
| Levered Free Cash Flow (TTM) | -49.42 M |
| Return on Assets (TTM) | -101.26% |
| Return on Equity (TTM) | -246.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunic, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.00 |
|
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.35% |
| % Held by Institutions | 44.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avidity Partners Management Lp | 31 Mar 2026 | 669,941 |
| 683 Capital Management, Llc | 31 Mar 2026 | 245,000 |
| Propel Bio Management, Llc | 31 Mar 2026 | 234,478 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |